Daniel Shao-Weng TAN

National Cancer Centre Singapore

Dr Daniel Tan is a Senior Consultant with the Division of Medical Oncology at National Cancer Centre Singapore (NCCS) and a Senior Clinician-scientist at Genome Institute of Singapore.  His main area of interest is in thoracic, head and neck malignancies and drug development.  He currently leads the phase I unit (Experimental Cancer Treatment Unit, ECRU) and is also the Principal Investigator of the Cancer Therapeutics Research Laboratory focused on developing representative patient derived preclinical models to gain insights to drug response and resistance. His research has won multiple international awards, including European Society of Medical Oncology Congress Travel Award, American Society of Clinical Oncology (ASCO) Merit Awards and an ASCO Young Investigator Award. Recent awards include the SingHealth GCEO Outstanding Clinician-Researcher Award and a National Medical Research Council Clinician-Scientist Award.  He has published in widely in journals including Nature, Nature Medicine, The New England Journal of Medicine, The Lancet Oncology and Journal of Clinical Oncology.